Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
6.
Med Mycol ; 56(8): 917-925, 2018 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-29267891

RESUMO

The clinical and microbiological characteristics of infections caused by Scedosporium/ Lomentospora species in 21 patients are described. We searched retrospectively the records for Scedosporium/ Lomentospora species seen at the University Hospital Virgen de las Nieves from 2006 to 2017. Out of them, 16 were male; mean age at diagnosis was 57.8 (±SD 15) years; all patients had risk factors for fungal infection such as corticosteroids and/or immunosuppressive treatment in 18 (85.7%) patients, pulmonary diseases in seven (33.3%) cases, hematological malignancies in six (28.5%), and organ transplantation in three (14.2%) patients. Most patients had infection in the lung/pleura (17/80.9%); cough was present in 12 patients and dyspnea in another 12, and the mean interval until diagnosis was 13.6 days. The most frequent species was S. apiospermum/S. boydii in 14 patients (66.6%), followed by L. prolificans in seven. The diagnosis was obtained from sputum in 12 (57.1%) cases, followed by pleural fluid and bronchoalveolar lavage in two of each. The most frequently used antifungals were voriconazole and amphotericin B, but combination of more than one antifungal drug was only used in three patients. Ten patients were cured, and six patients died as a consequence of the infection; three patients had chronic infection. In general, infections caused by Scedosporium/Lomentospora species are rare, serious, and difficult to diagnose and treat, having a high index or mortality especially in those caused by L. prolificans.


Assuntos
Ascomicetos/isolamento & purificação , Micoses/microbiologia , Micoses/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/uso terapêutico , Ascomicetos/classificação , Feminino , Hospitais Universitários , Humanos , Masculino , Pessoa de Meia-Idade , Micoses/tratamento farmacológico , Estudos Retrospectivos , Fatores de Risco , Espanha , Análise de Sobrevida , Resultado do Tratamento , Adulto Jovem
7.
Rev. esp. quimioter ; 30(5): 312-318, oct. 2017.
Artigo em Espanhol | IBECS | ID: ibc-167147

RESUMO

Streptococcus agalactiae, estreptococo del grupo B (EGB), es la mayor causa de morbi-mortalidad entre los neonatos y un patógeno importante entre los pacientes adultos inmunodeprimidos. A pesar de los avances en la prevención y tratamiento de la infección neonatal, fruto de la implantación de las recomendaciones nacionales e internacionales que en las últimas dos décadas se han desarrollado para ello, aún quedan pendientes mejoras para el control definitivo de la enfermedad. En este sentido, la vacunación frente a EGB podría ser una medida eficaz para la prevención de la infección en aquellos casos donde la profilaxis intraparto no es útil y en pacientes adultos con factores de riesgo de desarrollar infección invasiva por EGB. Esta revisión resume los esfuerzos llevados a cabo para controlar esta infección y aporta información sobre el estado actual de las vacunas frente a EGB empleando diferentes estrategias en su diseño (AU)


Streptococcus agalactiae, group B Streptococcus (SGB), is the most important cause of morbi-mortality among newborn population, and an important pathogen among immunossupressed adult patients. Despite the advances in the treatment and prevention of neonatal infections as a consequence of implementation of national and international recommendations for prevention of infection, there are still some improvements for the final control of the disease. In this sense, the vaccination against SGB could be an effective measure for the prevention of disease in those cases where intrapartum prophylaxis is not useful and in adult patients with risk factors for invasive infection due to SGB. This review summarizes the efforts made until now in order to establish the control of the infection, and brings some information on the current state-of-the art of vaccines against SGB, in which different strategies in their design have been used (AU)


Assuntos
Humanos , Recém-Nascido , Adulto , Streptococcus agalactiae , Vacinas , Infecções/imunologia , Infecções Estreptocócicas/imunologia , Infecções Estreptocócicas/prevenção & controle , Terapia de Imunossupressão , Estratégias de Saúde , Vacinação/métodos , Vacinas Conjugadas/administração & dosagem , Streptococcus agalactiae/imunologia , Vacinas Conjugadas/imunologia
8.
J Virol Methods ; 237: 38-39, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27575683

RESUMO

Serological confirmation of measles is achieved by detecting the specific immunoglobulin M (IgM), and it is important to evaluate new commercial inmunoassays in order to ensure the quality of results. The objective of this study was to compare the performance of a novel automated chemiluminescent immunoassay (CLIA), Virclia IgM measles (Vircell, Spain), with that of the widely used Liaison measles IgM assay (DiaSorin, Italy). A panel of 86 sera from laboratory-confirmed cases was used for the sensitivity calculation, and 59 sera from healthy individuals and those with other viral infections were used for the specificity calculation. Sensitivity values were 96.5% for Virclia and 97.6% for Liaison; specificity values were 93.2% for Virclia and 96.6% for Liaison; neither difference was statistically significant VirClia IgM measles is a good alternative to other immunoassays for the serological confirmation of measles.


Assuntos
Anticorpos Antivirais/sangue , Imunoensaio/métodos , Imunoglobulina M/sangue , Medições Luminescentes , Vírus do Sarampo/imunologia , Sarampo/diagnóstico , Sarampo/imunologia , Humanos , Imunoensaio/normas , Técnicas Imunoenzimáticas/métodos , Imunoglobulina G/sangue , Itália , Sarampo/virologia , Vírus do Sarampo/isolamento & purificação , Kit de Reagentes para Diagnóstico , Sensibilidade e Especificidade , Testes Sorológicos/métodos , Espanha
9.
Rev. esp. quimioter ; 29(4): 214-219, ago. 2016. tab
Artigo em Espanhol | IBECS | ID: ibc-156108

RESUMO

Introducción. La infección protésica tardía se presenta a partir del segundo mes tras la cirugía en el contexto de una diseminación hematógena desde otro foco. La infección protésica por micobacterias es una complicación rara cuyo manejo clínico no está estandarizado. Caso. Paciente de 77 años sin antecedentes personales de interés salvo diabetes y un recambio protésico de rodilla derecha por gonartrosis tres años antes. Acude a urgencias del hospital por un cuadro de unos 6 meses de evolución de intenso dolor en rodilla derecha de tipo mecánico con signos inflamatorios pero sin fiebre asociada. A los 5 días de su reingreso y presentando empeoramiento clínico se informa del crecimiento de Mycobacterium tuberculosis en la primera muestra de aspirado de rodilla y se instaura tratamiento antituberculoso durante 9 meses. Las imágenes de resonancia magnética nuclear confirmaron también el diagnóstico de espondilitis tuberculosa en el contexto clínico de la paciente. Tras la intervención quirúrgica se seguía aislando en el cultivo de las muestras intraoperatorias M. tuberculosis y por ello la paciente recibió de nuevo otra tanda de 9 meses con antituberculosos. La evolución al año de seguimiento fue aceptable, aunque unos meses después la paciente falleció por causas cardiovasculares. En la revisión bibliográfica se encontraron 15 publicaciones con un total de 17 casos clínicos en los últimos 25 años de infección protésica por M. tuberculosis. Conclusión. La artritis protésica tuberculosa, aunque es una presentación infrecuente, debe tenerse presente, especialmente en aquellos pacientes con condiciones predisponentes y con antecedentes de infección tuberculosa (AU)


Introduction. Prosthetic late infection occurs in the second month after surgery in the context of haematogenous spread from another source. Prosthetic mycobacterial infection is a rare complication whose clinical management is not standardized. Case. Patient of 77 years with no personal history except for diabetes and a prosthetic replacement of right knee with osteoarthritis three years ago. Patient goes to hospital emergency box for 6 months pain in the right knee with mechanical inflammatory signs but no fever associated. After their return within 5 days and clinical worsening is reporting growth of Mycobacterium tuberculosis in knee aspirate and antitubercular treatment is established for 9 months. Nuclear magnetic resonance imaging studies also confirmed the diagnosis of tuberculosis spondylitis in the clinical context of the patients. After surgery, M. tuberculosis was again isolated from intraoperative samples and therefore the patient received another batch of treatment for 9 months. After a year of monitoring, the development was acceptable but few months later, the patient died for cardiovascular causes. In the literature review, 15 publications with a total of 17 clinical cases of prosthetic infection by M. tuberculosis were found from 1980 to 2014. Conclusion. Prosthetic tuberculous arthritis, although it is a rare presentation, it should be noted, especially in patients with predisposing conditions with a history of tuberculosis infection (AU)


Assuntos
Humanos , Feminino , Idoso , Prótese do Joelho/microbiologia , Infecções Relacionadas à Prótese/diagnóstico , Tuberculose Osteoarticular/microbiologia , Mycobacterium tuberculosis/isolamento & purificação , Artroplastia do Joelho , Osteoartrite do Joelho/cirurgia
11.
J Med Microbiol ; 65(9): 910-914, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27389862

RESUMO

We present the first evaluation of a novel molecular assay, the Speed-Oligo Mycobacterium tuberculosis complex (SO-MTBC), which is based on PCR combined with a dipstick for the differentiation of M. tuberculosis complex (MTBC) members. The results of this assay were compared with findings obtained using the Genotype MTBC assay. In this study, 189 strains of MTBC isolates from 2011 to 2014 were evaluated to determine the MTBC species. Most (174, 92 %) of the strains were identified as M. tuberculosissensu stricto, 7 (3.7 %) as Mycobacteriumbovis, 5 (2.6 %) as M. bovis bacillus Calmette-Guérin, 2 (1.1 %) as Mycobacteriumafricanum and 1 (0.5 %) as Mycobacteriumcaprae; no strains belonged to Mycobacteriummicroti and Mycobacteriumcanettii subsp. The concordance κ coefficient obtained was 0.96 with the results of the Genotype MTBC assay. SO-MTBC may represent a fast and easy-to-use alternative for differentiating among MTBC subspecies in laboratories with standard equipment.


Assuntos
Técnicas de Diagnóstico Molecular/métodos , Mycobacterium tuberculosis/classificação , Mycobacterium tuberculosis/genética , Kit de Reagentes para Diagnóstico , Tuberculose/diagnóstico , Tuberculose/microbiologia , Humanos , Hibridização de Ácido Nucleico/métodos , Reação em Cadeia da Polimerase/métodos
12.
Mycopathologia ; 181(9-10): 745-52, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27300341

RESUMO

Fungal keratitis is a severe ocular infection that primarily affects subjects engaged in outdoor activities. Risk factors include allergic conjunctivitis, previous eye surgery, previous treatment with wide-spectrum antimicrobial agents and corticosteroids and using contact lenses. Corneal infection is usually secondary to trauma involving organic material, which is often the only predisposing factor. Early diagnosis based on clinical examination and microbiological investigation (microscopy, cultures and molecular techniques) is crucial to selecting the appropriate antifungal therapy and prevent progression. We report the case of a patient with keratitis due to Beauveria bassiana, an opportunistic and entomopathogenic filamentous fungus that is used as a biological insecticide and which is a rare cause of corneal infection. We review previous cases reports of B. bassiana keratitis published and its main features to compare with our case, a female occasional agriculture worker who had not suffered any trauma involving organic material. The patient received topical and oral antifungal therapy and debridement surgery, with a satisfactory outcome.


Assuntos
Beauveria/isolamento & purificação , Lentes de Contato/efeitos adversos , Ceratite/etiologia , Ceratite/patologia , Micoses/diagnóstico , Micoses/patologia , Antifúngicos/administração & dosagem , Beauveria/classificação , Beauveria/genética , Desbridamento , Feminino , Humanos , Ceratite/terapia , Pessoa de Meia-Idade , Micoses/terapia , Resultado do Tratamento
14.
Rev. chil. infectol ; 32(6): 706-709, ilus
Artigo em Espanhol | LILACS | ID: lil-773278

RESUMO

Intravesical therapy with live-attenuated Mycobacterium bovis strain have demonstrated to be effective in the treatment of recurrent and high-grade superficial bladder tumors. The use of this therapy is widely extended; however spreading of bacillus from the injection site could be one rare complication that may cause infection in different locations. An appropriate anamnesis is very important to establish an etiological diagnostic of possible infections caused by M. bovis BCG. Laboratory diagnosis at species level is difficult because of the high genetic similarity (99.9%) with the other member of Mycobacterium tuberculosis complex. We present a case report who developed tuberculous spondylodiscitis by M. bovis BCG, which had a history of intravesical instillation for treatment of bladder cancer.


Las instilaciones intravesicales con la cepa viva atenuada de Mycobacterium bovis han demostrado su eficacia en el tratamiento de cáncer urotelial de vejiga. Su uso está ampliamente difundido; sin embargo, una reacción adversa infrecuente es la extravasación del bacilo del lugar de acción pudiendo causar infecciones en otras localizaciones. Una correcta anamnesis del paciente ayuda a orientar la etiología de posibles infecciones relacionadas con éste microorganismo. El diagnóstico de laboratorio a nivel de especie es dificultoso ya que comparte un 99,9% de identidad genética con los otros miembros del complejo Mycobacterium tuberculosis. Se presenta el caso de un paciente que desarrolló una espondilodiscitis tuberculosa por M. bovis BCG, el cual tenía antecedentes de instilaciones intravesicales para el tratamiento del cáncer de vejiga.


Assuntos
Idoso , Humanos , Masculino , Abscesso/microbiologia , Discite/microbiologia , Mycobacterium bovis , Doenças da Medula Espinal/microbiologia , Abscesso/diagnóstico , Discite/diagnóstico , Imageamento por Ressonância Magnética , Doenças da Medula Espinal/diagnóstico
15.
Diagn Microbiol Infect Dis ; 83(3): 252-6, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26283523

RESUMO

The analytical performance of mariPOC® respi test (ArcDia® Laboratories, Turku, Finland) was evaluated using nucleic acid amplification techniques (NAATs) as the gold standard. The mariPOC assay allows automated detection of antigens from 8 respiratory viruses: influenza A and B viruses, respiratory syncytial virus, adenovirus, human metapneumovirus, and parainfluenza viruses 1-3. Positive results from samples with high viral load are available in 20min. Nasopharyngeal aspirates (n=192) from patients with acute respiratory infection and from previously positive samples were analyzed by mariPOC and NAATs (Simplexa(TM) FluA/FluB & RSV kit [n=118] and Luminex® Respiratory virus panel xTAG® RVP FAST [n=74]). Sensitivity, specificity, positive predictive value, and negative predictive value of mariPOC were 85.4%, 99.2%, 95.9%, and 97%, respectively, and 84.6% of positive results were reported in 20min. The good analytical performance and extended portfolio of mariPOC show this rapid assay as a good alternative for the etiological diagnosis of acute respiratory infection in laboratories that are not equipped with molecular assays.


Assuntos
Antígenos Virais/análise , Automação Laboratorial/métodos , Imunoensaio/métodos , Sistemas Automatizados de Assistência Junto ao Leito , Infecções Respiratórias/diagnóstico , Viroses/diagnóstico , Vírus/isolamento & purificação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Recém-Nascido , Pessoa de Meia-Idade , Nasofaringe/virologia , Valor Preditivo dos Testes , Sensibilidade e Especificidade , Fatores de Tempo , Vírus/classificação , Adulto Jovem
16.
Rev Chilena Infectol ; 32(6): 706-9, 2015 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-26928510

RESUMO

Intravesical therapy with live-attenuated Mycobacterium bovis strain have demonstrated to be effective in the treatment of recurrent and high-grade superficial bladder tumors. The use of this therapy is widely extended; however spreading of bacillus from the injection site could be one rare complication that may cause infection in different locations. An appropriate anamnesis is very important to establish an etiological diagnostic of possible infections caused by M. bovis BCG. Laboratory diagnosis at species level is difficult because of the high genetic similarity (99.9%) with the other member of Mycobacterium tuberculosis complex. We present a case report who developed tuberculous spondylodiscitis by M. bovis BCG, which had a history of intravesical instillation for treatment of bladder cancer.


Assuntos
Abscesso/microbiologia , Discite/microbiologia , Mycobacterium bovis , Doenças da Medula Espinal/microbiologia , Abscesso/diagnóstico , Idoso , Discite/diagnóstico , Humanos , Imageamento por Ressonância Magnética , Masculino , Doenças da Medula Espinal/diagnóstico
17.
J Clin Microbiol ; 51(1): 77-82, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23100355

RESUMO

We present the first evaluation of a novel molecular assay, the Speed-oligo Direct Mycobacterium tuberculosis (SO-DMT) assay, which is based on PCR combined with a dipstick for the detection of mycobacteria and the specific identification of M. tuberculosis complex (MTC) in respiratory specimens. A blind evaluation was carried out in two stages: first, under experimental conditions on convenience samples comprising 20 negative specimens, 44 smear- and culture-positive respiratory specimens, and 11 sputa inoculated with various mycobacterium-related organisms; and second, in the routine workflow of 566 fresh respiratory specimens (4.9% acid-fast bacillus [AFB] smear positives, 7.6% MTC positives, and 1.8% nontuberculous mycobacteria [NTM] culture positives) from two Mycobacterium laboratories. SO-DMT assay showed no reactivity in any of the mycobacterium-free specimens or in those with mycobacterium-related organisms. Compared to culture, the sensitivity in the selected smear-positive specimens was 0.91 (0.92 for MTC and 0.90 for NTM), and there was no molecular detection of NTM in a tuberculosis case or vice versa. With respect to culture and clinical data, the sensitivity, specificity, and positive and negative predictive values for the SO-DMT system in routine specimens were 0.76 (0.93 in smear positives [1.0 for MTC and 0.5 for NTM] and 0.56 in smear negatives [0.68 for MTC and 0.16 for NTM]), 0.99, 0.85 (1.00 in smear positives and 0.68 in smear negatives), and 0.97, respectively. Molecular misidentification of NTM cases occurred when testing 2 gastric aspirates from two children with clinically but not microbiologically confirmed lung tuberculosis. The SO-DMT assay appears to be a fast and easy alternative for detecting mycobacteria and differentiating MTC from NTM in smear-positive respiratory specimens.


Assuntos
Técnicas Bacteriológicas/métodos , Técnicas de Diagnóstico Molecular/métodos , Mycobacterium tuberculosis/isolamento & purificação , Escarro/microbiologia , Tuberculose Pulmonar/diagnóstico , Humanos , Mycobacterium tuberculosis/genética , Oligonucleotídeos , Sensibilidade e Especificidade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...